Winslow Asset Management Inc. Raises Holdings in STERIS plc (NYSE:STE)

Winslow Asset Management Inc. boosted its position in STERIS plc (NYSE:STE) by 0.9% during the third quarter, Holdings Channel.com reports. The fund owned 32,598 shares of the medical equipment provider’s stock after purchasing an additional 290 shares during the quarter. STERIS accounts for 1.5% of Winslow Asset Management Inc.’s holdings, making the stock its 25th largest holding. Winslow Asset Management Inc.’s holdings in STERIS were worth $7,906,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of STERIS by 0.8% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 220,866 shares of the medical equipment provider’s stock valued at $53,569,000 after purchasing an additional 1,706 shares in the last quarter. Venturi Wealth Management LLC lifted its position in STERIS by 45.4% during the third quarter. Venturi Wealth Management LLC now owns 1,837 shares of the medical equipment provider’s stock valued at $446,000 after buying an additional 574 shares in the last quarter. GDS Wealth Management grew its stake in STERIS by 8.0% during the third quarter. GDS Wealth Management now owns 55,155 shares of the medical equipment provider’s stock worth $13,377,000 after buying an additional 4,063 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of STERIS in the third quarter worth $25,000. Finally, Axxcess Wealth Management LLC purchased a new position in shares of STERIS in the 3rd quarter valued at $203,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Trading Up 1.2 %

Shares of STE opened at $221.86 on Tuesday. STERIS plc has a one year low of $195.47 and a one year high of $248.24. The stock has a 50-day moving average price of $232.29 and a 200 day moving average price of $227.97. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.49 and a current ratio of 2.41. The company has a market capitalization of $21.88 billion, a P/E ratio of 50.65 and a beta of 0.85.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.03 earnings per share. Sell-side analysts forecast that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.03%. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insider Transactions at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

STE has been the subject of a number of research reports. Stephens reaffirmed an “overweight” rating and set a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday. JMP Securities reiterated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. KeyCorp upped their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus target price of $253.00.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.